These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 28978103)

  • 41. Improved understanding of risk factors could help to reduce the incidence of hepatocellular carcinoma.
    Tong MJ
    Gastroenterol Hepatol (N Y); 2012 May; 8(5):320-1. PubMed ID: 22933863
    [No Abstract]   [Full Text] [Related]  

  • 42. Improving access to screening and treatment of hepatocellular carcinoma in the United States.
    Davis JPE; Rabiee A
    Clin Liver Dis (Hoboken); 2024; 23(1):e0219. PubMed ID: 38841196
    [No Abstract]   [Full Text] [Related]  

  • 43. Molecular Epidemiology of Hepatocellular Carcinoma.
    Hoshida Y
    Clin Liver Dis (Hoboken); 2012 Dec; 1(6):177-179. PubMed ID: 26213618
    [No Abstract]   [Full Text] [Related]  

  • 44. Surveillance for Hepatocellular Carcinoma.
    Frenette C
    Gastroenterol Hepatol (N Y); 2016 Jun; 12(6):394-6. PubMed ID: 27493599
    [No Abstract]   [Full Text] [Related]  

  • 45. Surveillance for Hepatocellular Carcinoma.
    Saab S
    Gastroenterol Hepatol (N Y); 2014 Nov; 10(11):745-747. PubMed ID: 28435411
    [No Abstract]   [Full Text] [Related]  

  • 46. Hepatocellular carcinoma surveillance: an open question.
    Biselli M; Garuti F; Neri A
    Hepatobiliary Surg Nutr; 2019 Aug; 8(4):431-432. PubMed ID: 31489324
    [No Abstract]   [Full Text] [Related]  

  • 47. Surveillance for hepatocellular carcinoma: in whom and how?
    El-Serag HB; Davila JA
    Therap Adv Gastroenterol; 2011 Jan; 4(1):5-10. PubMed ID: 21317990
    [No Abstract]   [Full Text] [Related]  

  • 48. [Considerations on the influence of sex according to ages in pathological states].
    LUMIERE A
    Avenir Med; 1947 Mar; 44(3):33-6. PubMed ID: 20247976
    [No Abstract]   [Full Text] [Related]  

  • 49. Hepatocellular carcinoma.
    Nat Rev Dis Primers; 2016 Apr; 2():16019. PubMed ID: 27227516
    [No Abstract]   [Full Text] [Related]  

  • 50. Hepatocellular carcinoma in Hispanics.
    Méndez-Sánchez N; Zamora-Valdés D; Vásquez-Fernández F; Uribe M
    Ann Hepatol; 2007; 6(4):279-80. PubMed ID: 18007562
    [No Abstract]   [Full Text] [Related]  

  • 51. Hepatocellular Carcinoma.
    Lichtenstein GR
    Gastroenterol Hepatol (N Y); 2015 Mar; 11(3):138. PubMed ID: 27099584
    [No Abstract]   [Full Text] [Related]  

  • 52. Hepatocellular carcinoma.
    Meng-Chao W
    HPB (Oxford); 2005; 7(1):3-4. PubMed ID: 18333155
    [No Abstract]   [Full Text] [Related]  

  • 53. Hepatocellular Carcinoma.
    Pawlik TM
    Surg Oncol Clin N Am; 2024 Jan; 33(1):xiii-xiv. PubMed ID: 37945149
    [No Abstract]   [Full Text] [Related]  

  • 54. Hepatocellular Carcinoma.
    Yopp AC; Majella Doyle MB
    Surg Oncol Clin N Am; 2024 Jan; 33(1):xv-xvi. PubMed ID: 37945150
    [No Abstract]   [Full Text] [Related]  

  • 55. THE AGE INCIDENCE OF CARCINOMA.
    Waugh TR; Fisher TL
    Can Med Assoc J; 1930 May; 22(5):619-27. PubMed ID: 20317808
    [No Abstract]   [Full Text] [Related]  

  • 56. A global view of hepatocellular carcinoma: trends, risk, prevention and management.
    Yang JD; Hainaut P; Gores GJ; Amadou A; Plymoth A; Roberts LR
    Nat Rev Gastroenterol Hepatol; 2019 Oct; 16(10):589-604. PubMed ID: 31439937
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epidemiology of Hepatocellular Carcinoma.
    McGlynn KA; Petrick JL; El-Serag HB
    Hepatology; 2021 Jan; 73 Suppl 1(Suppl 1):4-13. PubMed ID: 32319693
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration Database.
    Kaplan DE; Tan R; Xiang C; Mu F; Hernandez S; Ogale S; Li J; Lin Y; Shi L; Singal AG
    Cancers (Basel); 2024 Oct; 16(20):. PubMed ID: 39456602
    [No Abstract]   [Full Text] [Related]  

  • 59. ALBI grade for outcome prediction in patients affected by hepatocellular carcinoma treated with transarterial radioembolization.
    Gelardi F; Rodari M; Pini C; Zanca R; Artesani A; Tosi G; Chiti A; Sollini M
    Front Nucl Med; 2022; 2():934446. PubMed ID: 39354974
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mapping the Hidden Terrain of Hepatocellular Carcinoma: Exploring Regional Differences in Incidence and Mortality across Two Decades by Using the Largest US Datasets.
    Abboud Y; Shah VP; Bebawy M; Al-Khazraji A; Hajifathalian K; Gaglio PJ
    J Clin Med; 2024 Sep; 13(17):. PubMed ID: 39274469
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.